When Herrmann published a post last week saying that blogging doesn’t necessarily generate new business for lawyers, the blogosphere lit up like a Christmas tree. (The ornaments can be seen, among other places, here, here, here, here, here, and here.)
The on-line community told us that, if our blog
We’re still feasting from our notes of the ACI Drug and Device Conference in New York last month. This post combines our thoughts with the ideas of one of the speakers at the conference. (We’re not sure if that person cares to be identified here, so we’re not naming him or her — but not
This just in:
The Second Circuit has granted Eli Lilly’s petition under Rule 23(f) to review Judge Weinstein’s decision certifying a class in the Zyprexa litigation.
Our earlier posts about Judge Weinstein’s order are here and here.
The entire text of the Second Circuit’s docket entry reads:
1/15/09 Order FILED GRANTING motion leave to
This morning’s Washington Post, among other places, reports that there’s a movement afoot to cause the FDA to review all high-risk medical devices through pre-market approval, rather than the less rigorous pre-market notification (or “510(k)”) process.
That’s a mixed bag.
This would surely increase the time it takes to get new devices on the market,
Back in the antediluvian days when we were in law school, the practice we learned was to include Supreme Court denials of certiori as subsequent history when citing cases in briefs. We’ve pretty much been doing it ever since.
Lately, however, we’ve seen a lot fewer “cert. denied”s in the briefs other legal stuff we’ve
We’re hardly the first to report it, but the FDA has followed through with the draft guidance proposal that we discussed last year and thus has thawed a bit the agency’s cold war against truthful off-label “promotion.” If you’re familiar with that post, nothing we say here will come as any great surprise.
If
We have accidentally re-sent to subscribers to our blog a couple of old posts.
We apologize for this. We respect your time, struggle not to clutter your e-inbox, and are working to fix the technical glitch.
(We know you don’t want to hear our tale of woe, but we’re thinking of trying to upgrade to
Want to kick up some dirt in the blogosphere?
Publish a blog post about . . . blogging!
Herrmann’s post on Monday about “blogging as a business development tool” attracted some attention around the web. We welcome our new readers from the Wall Street Journal Law Blog (nice photo, Dan), Above the Law (which sent
This is the first of what we hope will be many guest posts by Bert Rein, a founding partner of Wiley Rein, LLP. Among many other accomplishments, Bert represents Wyeth in the pending Wyeth v. Levine appeal in the Supreme Court.
What follows are Bert’s own thoughts, for which he gets all the
Once upon a time, the phrase “global coordinating counsel” was a bluff. It meant that a firm was defending hundreds of cases for a client in the United States and had recently been asked to kibbitz on one little case filed in Belgium. The guys with a marketing bent seized on this opportunity, replacing the